Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Architecture of Selected Schizophrenia-Associated Regions: Co-location of Non-coding and Protein-Coding Genes.

Schizophrenia bulletin open·2026
Same author

PDE5A variation is associated with tadalafil response in men with diabetes mellitus and erectile dysfunction: a prospective proof-of-concept pharmacogenetic study.

The journal of sexual medicine·2026
Same author

Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Genetic variability of immune checkpoints in asbestos-related diseases.

Radiology and oncology·2026
Same author

MyomiR Networks in Spinal Muscular Atrophy: Associations With Clinical Severity and Treatment Response.

Molecular neurobiology·2026
Same author

The value and risks of antidepressant therapy in Alzheimer's disease: a field update and its clinical implications.

Expert review of neurotherapeutics·2026

Related Experiment Video

Updated: Jun 29, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

CYP 2D6 polymorphism and antipsychotic therapy.

Blanka Kores Plesnicar1, Vita Dolzan, Bojan Zalar

  • 1University Clinical Centre Maribor, Department of Psychiatry, and Medical faculty Maribor, Slovenia. blanka.kores@ukc-mb.si

Psychiatria Danubina
|October 2, 2008
PubMed
Summary

Genetic variations in the cytochrome P450 2D6 gene (CYP 2D6) may influence treatment outcomes for schizophrenia. This study investigated CYP2D6

Area of Science:

  • Pharmacogenetics
  • Clinical Psychiatry
  • Neuroscience

Background:

  • Inter-individual variability in antipsychotic treatment response presents a significant challenge in clinical psychiatry.
  • Previous research on the influence of cytochrome P450 2D6 (CYP 2D6) gene polymorphism on psychopathological and extrapyramidal symptoms yielded conflicting results.
  • A notable gap exists in clinical studies examining the long-term impact of CYP 2D6 polymorphism on the therapeutic efficacy for schizophrenia.

Purpose of the Study:

  • To assess the effect of CYP 2D6 genotype on psychopathological symptoms in patients with schizophrenia or schizoaffective disorder.
  • To evaluate the impact of CYP 2D6 genotype on extrapyramidal symptoms in patients undergoing long-term antipsychotic maintenance therapy.
  • To investigate the relationship between CYP 2D6 genetic variations and treatment outcomes in a Slovenian outpatient population.

Related Experiment Videos

Last Updated: Jun 29, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Main Methods:

  • Genotyping of the CYP 2D6 gene was performed.
  • Psychopathological and extrapyramidal symptoms were assessed in outpatients with schizophrenia or schizoaffective disorder.
  • Patients were in stable remission and receiving long-term maintenance antipsychotic therapy.

Main Results:

  • The study evaluated the association between specific CYP 2D6 genotypes and symptom profiles.
  • Analysis focused on differences in psychopathological and extrapyramidal symptoms based on CYP 2D6 genetic variations.
  • Results aimed to clarify the role of CYP 2D6 in long-term treatment response.

Conclusions:

  • The findings contribute to understanding the pharmacogenetic underpinnings of antipsychotic treatment response.
  • This research provides insights into the impact of CYP 2D6 polymorphism on schizophrenia and schizoaffective disorder management.
  • The study highlights the potential of CYP 2D6 genotyping for personalizing long-term antipsychotic therapy.